Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance)
Posted by Nexavar (Nexavar) on Sun, 26 Aug 2007 00:17:07 +0000
Bayer AG and Onyx Pharmaceuticals Inc. said Monday the Food and Drug Administration gave priority review for the application of its drug Nexavar as a liver cancer treatment.
Bayer erhält von FDA "Priority Review"-Status für Nexavar (OnVista)
Wie bewerten Sie diese Seite? sehr gut 1 2 3 4 5 6 schlecht © 1998-2007 OnVista Group - Die OnVista Media GmbH übernimmt keine Haftung für die Richtigkeit der Angaben!
Staff Writer (BioWorld)
On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products.
Nexawar from Bayer, ONYX gets priority status from US FDA (New Ratings)
NEW YORK, August 20 (newratings.com) – Bayer AG and ONYX Pharmaceuticals, Inc ( ONXX.NAS ) Monday announced that the new drug application for their jointly developed Nexavar drug was granted priority review status by the Food and Drug Administration (FDA).
German shares flat afternoon as Bayer, VW help offset weak financials, ZEW index (FinanzNachrichten)
FRANKFURT (Thomson Financial) - German shares were largely flat in afternoon trade as German indices took a momentary break from today's roller-coaster ride....
Original post: Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance) by Copyright (c) 2004 Yahoo! Inc. All rights reserved. at Yahoo! News Search Results for nexavar
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Posted by Nexavar (Nexavar) on Sat, 25 Aug 2007 23:17:24 +0000
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), ...
Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer
“This Priority Review underscores the potential of Nexavar to be a significant advance in the treatment of liver cancer,” said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. ...
Onyx Expects Early 2008 Launch For Nexavar In Liver Cancer
Firm expects more off-label use of Nexavar in liver cancer in second half of 2007.
Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of patients with hepatocellular ...
Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ......
Original post: Nexavar Granted FDA Priority Review for Treatment of Liver Cancer by at Google Blog Search: nexavar
Bayer/Onyx: Nexavar approval in liver cancer on the horizon (Pharmaceutical Business Review)
Posted by Nexavar (Nexavar) on Fri, 24 Aug 2007 00:25:25 +0000
Bayer and Onyxs Nexavar has been granted priority for hepatocellular carcinoma from the FDA and a final decision regarding its approval is now expected in the next few months. The drug has been shown to significantly extend overall survival in previously untreated patients, a population with a high unmet need, ensuring adoption as the standard of care for this patient group.
Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer (Medical News Today)
Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. [click link for full ...
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer (The San Francisco Examiner)
WAYNE, N.J. ( Map ) - Bayer HealthCare Pharmaceuticals (NYSE: BAY ) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. ...
Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority review (Sharewatch)
LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment of hepatocellular carcinoma, the most common form of liver cancer, has been accepted for review and granted priority review status by the US Food and Drug Administration.
Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance)
Bayer AG and ...
Original post: Bayer/Onyx: Nexavar approval in liver cancer on the horizon (Pharmaceutical Business Review) by Copyright (c) 2004 Yahoo! Inc. All rights reserved. at Yahoo! News Search Results for nexavar
Nexavar: Nexavar
Posted by Nexavar (Nexavar) on Wed, 22 Aug 2007 00:21:37 +0000
What is the most important information I should know about Nexavar? ... How can I get more information about insurance coverage for Nexavar? ...
Nexavar® : Onyx Pharmaceuticals
Changing the way cancer is treated ... Nexavar emerged from our collaboration with Bayer focused on identifying and ... Nexavar targets both the tumor cell and ...
FDA Approves New Treatment for Advanced Kidney Cancer
... Administration (FDA) today approved Nexavar (sorafenib tosylate), a new anti ... "The approval of Nexavar to treat advanced kidney cancer brings a much needed ...
NEXAVAR
NEXAVAR, a multikinase inhibitor targeting several serine/threonine and receptor ... Each red, round NEXAVAR film-coated tablet contains sorafenib tosylate ...
BRAND NAME Nexavar (Generic) (sorafenib)
... during the first 6 weeks of Nexavar therapy and thereafter monitored and treated, ... additional dose reduction is required, Nexavar may be reduced to a ......
Original post: Nexavar: Nexavar by Copyright (c) 2007 Yahoo! Inc. All rights reserved. at Yahoo! Search: nexavar
Onyx shares up after Bayer announces Nexavar sales - Reuters
Posted by Nexavar (Nexavar) on Tue, 21 Aug 2007 23:19:45 +0000
TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... - HemscottBayer: sales growth from Schering but future focus on Nexavar - Pharmaceutical Business Review
Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority ...
Posted by Nexavar (Nexavar) on Tue, 21 Aug 2007 13:02:55 +0000
Forbes - LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment of hepatocellular carcinoma, the most common form of liver cancer, has been accepted for ...
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Earthtimes - WAYNE, N.J., and EMERYVILLE, Calif., Aug. 20 -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with ...
FDA gives Onyx liver cancer drug priority review
Reuters - BOSTON, Aug 20 (Reuters) - Onyx Pharmaceuticals Inc. (ONXX.O: Quote , Profile , Research ) and German partner Bayer AG (BAYG.DE: Quote , Profile , Research ) said on Monday that U.S. regulators agreed to review their drug Nexavar as a treatment for ...
Bayer HealthCare (BAY) and Onyx (ONXX) Announce FDA Grants Priority ...
StreetInsider.com - Bayer HealthCare (BAY) and Onyx (ONXX) Announce FDA Grants Priority Review for Nexavar in Treatment of Liver Cancer Dendreon (DNDN) Announces Positive Phase 1 Study of Neuvenge in Breast Cancer Indevus Phama (IDEV) Receives FDA 'Approvable Letter ...
Onyx, Bayer Drug Gets Priority Review
Forbes - Bayer AG and Onyx Pharmaceuticals Inc. said Monday the Food and Drug Administration gave priority review for the application of its drug Nexavar as a liver cancer treatment. The drug is already approved in more than 50 countries to treat advanced ... ...
Original post: Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority ... by Copyright © 2007 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Live Search results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions. at Live Search News: nexavar
Bayer: sales growth from Schering but future focus on Nexavar (Pharmaceutical Business Review)
Posted by Nexavar (Nexavar) on Sun, 12 Aug 2007 00:15:22 +0000
Bayer Schering has reported robust second quarter sales, and an overall positive performance during the first half of the year, boosted by strong product lines such as Yasmin and Betaferon which were gained from the acquisition of Schering AG in 2006. However, the leading German pharmaceutical companys future focus relies heavily on the new oncology treatment Nexavar.
Onyx shares up after Bayer announces Nexavar sales (Reuters via Yahoo! Singapore News)
LOS ANGELES, Aug 7 - Shares in Onyx Pharmaceuticals Inc. rose as much a 9 percent after partner Bayer reported a 161 rise in sales of their cancer drug Nexavar.
Onyx Shines on Nexavar Sales (TheStreet.com)
Strong demand for the kidney-cancer drug sends shares up 8%.
Onyx Pharmaceuticals 2Q Loss Narrows (AP via Yahoo! Finance)
Onyx Pharmaceuticals Inc. said late Tuesday its second-quarter loss narrowed on lower operating expenses and a payment from Bayer for the liver cancer drug Nexavar.
Elderly parents of cancer sufferer forced to sell home to fund treatment (Daily Mail)
The elderly parents of a man denied a life-prolonging cancer drug said they will sell their home to help him survive. Ken and Irene Potts, both 78, said they would 'live in a tent' if the drug could help their sick son Ken ...
Original post: Bayer: sales growth from Schering but future focus on Nexavar (Pharmaceutical Business Review) by Copyright (c) 2004 Yahoo! Inc. All rights reserved. at Yahoo! News Search Results for nexavar
new to nexavar
Posted by Nexavar (Nexavar) on Tue, 07 Aug 2007 00:15:49 +0000
Hello againMy mum has stage 4 RCCShe is on day 4 of nexavar treatment, very bad diarrhoea from day one and tongue quite sore and hot feet. She is also on her third course of zometa. Her breathing is very fast and shallow, which recently ...
Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of with hepatocellular ...
WHERE CAN I FIND NEXAVAR AND WHAT DOES IT COST
The oncologist said my dad must get Nexavar but you cannot get it in South Africa. I was told that you can get it easily in London, America and Mexico.Can someone PLEASE help me and tell me where I can find it and more importantly, ...
Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ...
Bayer: Phase 3 Study: Nexavar Significantly Extends Overall ...
The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those ......
Original post: new to nexavar by at Google Blog Search: nexavar
The Top 20 Cancer Therapy Brands Are Forecast to Experience 144 Different Events between 2007 and 2016 (Business Wire via Yahoo! Finance)
Posted by Nexavar (Nexavar) on Sun, 29 Jul 2007 09:15:25 +0000
DUBLIN, Ireland----Research and Markets has announced the addition of Commercial Insight: Top 20 Cancer Therapy Brands - Sales of Targeted Therapies Overtake Cytotoxics in 2006 to their offering.
Learn about the Top 20 Cancer Therapy Brands - Sales of Targeted Therapies Overtake Cytotoxics in 2006 (Business Wire via Yahoo! Finance)
LYON, France----Reportlinker.com announces that a new market research report related to the worldwide oncology industry is now available to its catalogue.
Overview of Hepatocellular Carcinoma Provided by New Report (Business Wire via Yahoo! Finance)
DUBLIN, Ireland----Research and Markets has announced the addition of "Stakeholder Opinions: Hepatocellular Carcinoma - Opportune Indication For Novel Therapies" to their offering.
Slight Setback for ImClone (The Motley Fool)
ImClone announces a failed cancer study.
Cancer sufferer Ken starts course of drug treatment (Blyth and Wansbeck Today)
A BLYTH caretaker battling cancer has just started a course of tablets costing thousands of pounds per month after a fundraising drive led by family, friends, and complete strangers. (10/07/2007 13:37:09)...
Original post: The Top 20 Cancer Therapy Brands Are Forecast to Experience 144 Different Events between 2007 and 2016 (Business Wire via Yahoo! Finance) by Copyright (c) 2004 Yahoo! Inc. All rights reserved. at Yahoo! News Search Results for nexavar
Pages: Start 1
|
|
